Cadence Pharmaceuticals tapped Scott Byrd as SVP and chief commercial officer. Byrd’s responsibilities will include sales, marketing and supply operations. He will report directly to Ted Schroeder, president and CEO. Byrd was most recently US brand leader, prasugrel, at Lilly, where he was responsible for all commercial planning and marketing activities in the US prior to the launch. Before that, he worked as senior director, global brands, cardiovascular and acute care for Lilly; he also served as director of sales and marketing for Lilly’s cardiovascular business unit.
MacroGenics, a private biotech focused on autoimmune disorders, cancer and infectious diseases, elected Paulo Costa to its board of directors. Costa was previously president and CEO at Novartis U.S. Before Novartis, Costa worked at J&J for 30 years, serving as president of Janssen Pharmaceutica, and other positions. The election follows the retirement of MacroGenics director John Maraganore.
Interactive agency Rosetta hired Gary Scheiner to the newly-created position of chief creative officer. Scheiner was previously an executive creative director at TBWAChiatDay. Before that, he served as EVP, executive creative director and co-managing director of Rivet Global; prior to that, he worked under the same title at FCBi, New York. will be based in Rosetta’s New York office.
